Personalised And Generalised Integrated Biomaterial Risk Assessment

PANBioRA will provide a set of tools, composed of protocols and instruments standardising the evaluation of new biomaterials.

Today, biomaterial-based solutions play an important role in clinical applications.
They can be implemented e.g. astissue repair scaffolds or replace elements of damaged body parts. As these biomaterials directly interact with the human body, unforseen adverse reactions can occur.
PANBioRA will develop a tool to better assess a patient-specific reaction to biomaterials and thus allow improved clinical outcomes.

PANBioRA Timeline

What does PANBioRA provide?

The right solution at the right time 

The complexity of the new generation of biomaterials and implants put a lot of pressure on the relevance of the current testing methods. In addition, there is a policy-level awareness of the need for new instrumentation. PANBioRA directly tackles the ongoing trends and needs of personalised medicine and point-of-care devices with an integrated multifunctional system with game-changer potential. 

Antibody testing

Patient-specific interactions between biomaterials and the immune system will be assessed using the ground-breaking Mimotope Variation Analysis technology. 

Biomaterial testing

Biochemical responses of cells to the presence of biomaterials will be monitored in real time and integrated biosensors. In addition, the project will quantify the risk of cyto- and genotoxicity of new materials and their degradation products using mini-microscopes.

Cell testing

Real-time electrochemical sensing will be used to determine the cellular response to a given biomaterial. A set of cytokines released to the extracellular environment will be used as biomarkers to assess the cell response to different biomaterials.

Organ on a chip

Respiratory epithelium, gut and liver tissues will be miniaturized into organoids on chip to allow the determination of possible systemic and target organ-specific effects in both healthy and disease conditions.


Potential risks that are difficult to assess experimentally – such as explosion hazards and full-scale biomaterial/microbiota interactions – will be covered by simulations developed within the project.

Data analysis

The readouts of the modules will be fed into a model developed within PANBioRA using known biocompatible and hazardous materials to provide a quantitative risk assessment.

Risk rating

PANBioRA will develop a risk rating system that will display the suitability of the tested biomaterial using well characterized materials as reference.

World Biomaterial Congress 2020 Workshop


Biomaterial-related Advances
General Advantages

PANBioRA Numbers

PANBioRA will decrease healthcare burden stemming from implant related complications by 50%
implant related complications 50%
30% reduction in cost and time for testing biomaterials
cost and time for testing biomaterials 70%
Decreasing testing load by 50% through integration of experimental results and modelling in anencompassing predictive testing model (virtual biomaterial testing)
overall testing load 50%
Predictive capacities with > 90% fidelity compared to conventional methods
overall testing load 90%
Time for biomaterial risk assessment is reduced by at least 30%
biomaterial risk assessment time 70%
Whole fabrication and maintenance of PANBioRA 50% cheaper than mainstream mili-scale bioreactors and organ-on-chip models
fabrication and maintenance costs 50%
The 30% reduction in cost and time for testing biomaterials alone could translate into over $ 6-30 Million savings for a single material and shorten development time by 2-3 years.

Join the PANBioRA Network

PANBioRA Consortium